Methicillin Resistant Staphylococcus Aureus Drugs Market Analysis | CMI

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS
MARKET ANALYSIS

• Methicillin-Resistant Staphylococcus Aureus
  (MRSA) Drugs Market, By Drug class (Glycopeptides
  and Lipoglycopeptides, Oxazolidinones,
  Lipopeptides, Cephalosporin, Tetracycline, and
  Others), by Distribution Channel (Hospital
  Pharmacies, Retail Pharmacies, and Online
  Pharmacies), and by Region (North America, Latin
  America, Europe, Asia Pacific, Middle East, and
  Africa) - Size, Share, Outlook, and Opportunity
  Analysis 2018 - 2026
• The global methicillin-resistant staphylococcus
  aureus (MRSA) drugs market is estimated to be
  valued at US 922.2 million in 2018, and is
  expected to register a CAGR of 4.1 during the
  forecast period (20182026).

3
Figure 1. Global Methicillin-resistant
Staphylococcus aureus (MRSA) drugs Market Share
(), By Drug Class, (2018 2026)
4
Market Drivers

• Increasing Regulatory Approvals for Drugs Is
  Expected to Drive Global Methicillin-Resistant
  Staphylococcus Aureus (MRSA) Drugs Market Growth
• Approvals and launches of affordable generic
  medication is expected to drive the global
  methicillin-resistant Staphylococcus aureus
  (MRSA) drugs market growth over the forecast
  period. For instance, in 2015, Glenmark
  Pharmaceuticals received the approval from the
  U.S. Food and Drug Administration (FDA) for the
  generic version of the anti-bacterial drug,
  Zyvox. Moreover, in 2015, Allergan Plc. received
  the U.S. FDA approval for supplemental new drug
  application (sNDA) to update the label of Teflaro
  (ceftaroline fosamil) for treating adult patients
  with acute bacterial skin and skin structure
  infections (ABSSSI), and community-acquired
  bacterial pneumonia (CABP).
• Furthermore, strategic agreements and
  collaborations by market players regarding
  distribution of MRSA drugs are expected to drive
  the market growth. For instance, in 2016, Basilea
  Pharmaceutica Ltd. entered into a supply,
  distribution, and license agreement with Grupo
  Biotoscana S.L., for Basilea's antifungal
  CRESEMBA (isavuconazole) and antibiotic Zevtera
  (ceftobiprole) in 19 countries of Latin America
  along with Brazil, Mexico, Argentina, and
  Colombia.

5
Market Restraints

• However, declining patient pool having infections
  caused by MRSA pathogen is expected to restrain
  growth of the global methicillin-resistant
  staphylococcus aureus (MRSA) drugs market.
  According to the Centers for Disease Control and
  Prevention, hospital associated MRSA infections
  declined by 54 between 2005 and 2011 owing to
  increasing awareness about personal and public
  hygiene among the populace. This, in turn, is
  expected to reduce demand for the drugs.

6
Market Regional Analysis

• Regional segmentation of the global
  methicillin-resistant staphylococcus aureus
  (MRSA) drugs market includes North America, Latin
  America, Europe, Asia Pacific, Middle East, and
  Africa.
• Among region, North America is expected to hold a
  dominant position in the global
  methicillin-resistant staphylococcus aureus
  (MRSA) drugs market, and is expected to witness
  significant growth over the forecast period,
  owing to increasing health awareness, favorable
  reimbursement scenario, rising healthcare
  expenditure, and increasing number of approvals
  and launches of MRSA drugs. For instance, in
  2016, Allergan Plc. received the U.S. Food and
  Drug Administration (FDA) approval for its
  supplemental new drug application (sNDA) to
  update the label for Dalvance (dalbavancin) for
  injection.
• Moreover, Asia Pacific is expected to witness
  significant growth over the forecast period,
  owing to a larger patient pool, and expansion
  strategies adopted by market players to increase
  their market presence. For instance, in 2017,
  Basilea Pharmaceutica Ltd. entered into a
  licensed agreement with Shenzhen China Resources
  Gosun Pharmaceutical Co., Ltd. for expansion of
  Basilea's antibiotic Zevtera, a broad spectrum
  anti-bacterial, which can address MRSA in China,
  Hong Kong, and Macao.
• Furthermore, Europe is projected to witness
  significant market growth owing to launches and
  approvals of new drugs. For instance, in 2017,
  Cardiome Pharma Corp. launched Xydalba in Sweden,
  Finland, and the Republic of Ireland. Xydalba is
  approved by the European Medicines Agency (EMA)
  for treatment of acute bacterial skin and skin
  structure infections (ABSSSIs) in adults.

7
Figure 2 Global Methicillin-Resistant
Staphylococcus Aureus (MRSA) Drugs Market Share
(), By Region, (2018 2026)
8
Market Competitive Landscape

• Key players operating in the global
  methicillin-resistant staphylococcus aureus
  (MRSA) drugs market include Merck Co, Inc.,
  Pfizer, Inc., Allergan Plc., Teva Pharmaceutical
  Industries ltd, Melinta Therapeutics, Inc.,
  Cumberland Pharmaceuticals Inc., Nabriva
  Therapeutics Plc., Paratek Pharmaceuticals, Inc.,
  Debiopharm International S.A., and Innovation
  Pharmaceuticals Inc.

9

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Reference https//www.coherentmarketinsights.com
  /market-insight/methicillin-resistant-staphylococc
  us-aureus-mrsa-drugs-market-1538

10
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

11
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

12

• Thank You!
• Kindly follow CMI Social Media Profiles
  for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/